{"Clinical Trial ID": "NCT01735175", "Intervention": ["INTERVENTION 1:", "LA-EP2006", "During each chemotherapy cycle, eligible patients receive LA-EP2006 s.c. after the application of chemotherapy.", "LA-EP2006: Eligible patients should receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle, pegfilgrastim is injected s.c. post-chemotherapy application.", "INTERVENTION 2:", "- Neulasta\u00ae", "During each chemotherapy cycle, eligible patients receive Neulasta\u00ae s.c. after the application of chemotherapy.", "Neulasta\u00ae: Eligible patients should receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle, pegfilgrastim is injected s.c. after the application of chemotherapy."], "Eligibility": ["Incorporation criteria:", "Breast cancer proven by histology", "\u2022 Eligibility for six cycles of neoadjuvant or adjuvant chemotherapy", "- Exclusion criteria:", "Concomitant or anterior chemotherapy for breast cancer", "- Simultaneous or anterior anticancer treatment for breast cancer, such as endocrine treatment, immunotherapy, monoclonal antibodies and/or biological treatment", "\u2022 Concomitant prophylactic antibiotics", "Previous treatment with any G-CSF product (stimulating factor of the granulocyte column)", "Other inclusion/exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Average duration of severe neutropenia (SDN) during chemotherapy cycle 1", "Mean duration of severe neutropenia, defined as the number of consecutive days with ANC <0.5 \u00d7 10^9 cells/L (grade 4 neutropenia).", "Time limit: 21 days (Cycle 1 of chemotherapy treatment)", "Results 1:", "Title of arm/group: LA-EP2006", "Description of the arm/group: During each chemotherapy cycle, eligible patients receive an LA-EP2006 s.c. post-chemotherapy application.", "LA-EP2006: Eligible patients should receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle, pegfilgrastim is injected s.c. post-chemotherapy application.", "Total number of participants analysed: 159", "Average (standard deviation)", "Unit of measure: FAS days: 155 participants", "- 0.75 (0.878)", "PP: 146 participants", "- 0.75 (0.875)", "Results 2:", "Title of the arm/group: Neulasta", "Description of the arm/group: During each chemotherapy cycle, eligible patients receive a post-chemotherapy application for Neulasta s.c.", "Neulasta: Eligible patients are programmed to receive six cycles of chemotherapy every three weeks. During each cycle of chemotherapy pegfilgrastim is injected s.c. post-chemotherapy application.", "Total number of participants analysed: 157", "Average (standard deviation)", "Unit of measure: FAS days: 155 participants", "- 0.83 (0.898)", "PP: 149 participants", "- 0.79 (0.872)"], "Adverse Events": ["Undesirable Events 1:", "Total: 16/159 (10.06 per cent)", "9/159 (5.66%)", "Neutropenia 3/159 (1.89%)", "Anemia 1/159 (0.63%)", "Leucopenia 0/159 (0.00 %)", "Pancytopenia 0/159 (0.00 %)", "Thrombocytopenia 0/159 (0.00 %)", "Cardiorespiratory arrest 2/159 (1.26%)", "Cardiac arrest 1/159 (0.63%)", "Diarrhoea 0/159 (0.00 %)", "Gastritis 1/159 (0.63%)", "Nausea 1/159 (0.63%)", "Vomiting 0/159 (0.00 %)", "Adverse Events 2:", "Total: 21/157 (13.38 per cent)", "12/157 (7.64 per cent)", "Neutropenia 6/157 (3.82%)", "Anemia 2/157 (1.27%)", "- Leucopenia 1/157 (0.64%)", "Pancytopenia 1/157 (0.64%)", "Thrombocytopenia 1/157 (0.64%)", "- Cardiorespiratory arrest 0/157 (0.00 %)", "Cardiac arrest 0/157 (0.00 %)", "Diarrhoea 1/157 (0.64%)", "Gastritis 0/157 (0.00 %)", "Nausea 0/157 (0.00 %)", "Vomiting 1/157 (0.64%)"]}